Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Fusidic Acid Inhibits Hepatic Transporters and Metabolic Enzymes: Potential Cause of Clinical Drug-Drug Interaction Observed with Statin Coadministration.

Gupta A, Harris JJ, Lin J, Bulgarelli JP, Birmingham BK, Grimm SW.

Antimicrob Agents Chemother. 2016 Sep 23;60(10):5986-94. doi: 10.1128/AAC.01335-16. Print 2016 Oct.

2.

Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents.

Guo J, Joubran C, Luzietti RA Jr, Basarab GS, Grimm SW, Vishwanathan K.

Xenobiotica. 2017 Jan;47(1):31-49. doi: 10.3109/00498254.2016.1156186. Epub 2016 Apr 28.

PMID:
27122100
3.

Pharmacokinetics, metabolism and excretion of [(14)C]-lanicemine (AZD6765), a novel low-trapping N-methyl-d-aspartic acid receptor channel blocker, in healthy subjects.

Guo J, Zhou D, Grimm SW, Bui KH.

Xenobiotica. 2015 Mar;45(3):244-55. doi: 10.3109/00498254.2014.966175. Epub 2014 Sep 26.

PMID:
25259653
4.

Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct.

Gu C, Elmore CS, Lin J, Zhou D, Luzietti R, Dorff P, Grimm SW.

Drug Metab Dispos. 2012 Jun;40(6):1151-63. doi: 10.1124/dmd.112.044636. Epub 2012 Mar 7.

PMID:
22397852
5.

A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.

Zhou D, Sunzel M, Ribadeneira MD, Smith MA, Desai D, Lin J, Grimm SW.

Br J Clin Pharmacol. 2012 Jul;74(1):98-108. doi: 10.1111/j.1365-2125.2011.04155.x.

6.

In vitro and in vivo metabolism of a selective δ-opioid receptor.

Guo J, Gu C, Zhou D, Elmore CS, Bui KH, Grimm SW.

Drug Metab Dispos. 2011 Oct;39(10):1883-94. doi: 10.1124/dmd.111.040980. Epub 2011 Jul 13.

PMID:
21752944
7.

Disposition and metabolism of ticagrelor, a novel P2Y12 receptor antagonist, in mice, rats, and marmosets.

Li Y, Landqvist C, Grimm SW.

Drug Metab Dispos. 2011 Sep;39(9):1555-67. doi: 10.1124/dmd.111.039669. Epub 2011 Jun 13.

PMID:
21670219
8.

Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition.

Guo J, Zhou D, Grimm SW.

J Pharm Biomed Anal. 2011 Jul 15;55(5):964-71. doi: 10.1016/j.jpba.2011.03.034. Epub 2011 Mar 29.

PMID:
21497036
9.

In vitro metabolism of α7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite.

Zhou D, Zhang M, Ye X, Gu C, Piser TM, Lanoue BA, Schock SA, Cheng YF, Grimm SW.

Xenobiotica. 2011 Mar;41(3):232-42. doi: 10.3109/00498254.2010.536855. Epub 2011 Jan 13.

PMID:
21226652
10.

Absorption, excretion, and metabolism of a potential GABA-A α2/3 receptor modulator in rats.

Guo J, Davis PC, Gu C, Grimm SW.

Xenobiotica. 2011 May;41(5):385-99. doi: 10.3109/00498254.2010.545453. Epub 2011 Jan 6.

PMID:
21210737
11.

In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics.

Zhou D, Andersson TB, Grimm SW.

Drug Metab Dispos. 2011 Apr;39(4):703-10. doi: 10.1124/dmd.110.037143. Epub 2010 Dec 22.

PMID:
21177984
12.

In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies.

Li Y, Zhou D, Ferguson SS, Dorff P, Simpson TR, Grimm SW.

Xenobiotica. 2010 Nov;40(11):721-9. doi: 10.3109/00498254.2010.512670.

PMID:
20937004
13.

Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells.

Zhou D, Linnenbach AJ, Liu R, Luzietti RA, Harris JJ, Booth-Genthe CL, Grimm SW.

Drug Metab Dispos. 2010 Jul;38(7):1015-8. doi: 10.1124/dmd.110.033068. Epub 2010 Apr 9.

PMID:
20382755
14.

Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine.

Zhou D, Guo J, Linnenbach AJ, Booth-Genthe CL, Grimm SW.

Drug Metab Dispos. 2010 May;38(5):863-70. doi: 10.1124/dmd.109.030981. Epub 2010 Feb 4.

PMID:
20133892
15.

The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America.

Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KH, Lu C, Nomeir AA, Seibert E, Skordos KW, Tonn GR, Van Horn R, Wang RW, Wong YN, Yang TJ, Obach RS.

Drug Metab Dispos. 2009 Jul;37(7):1355-70. doi: 10.1124/dmd.109.026716. Epub 2009 Apr 9.

PMID:
19359406
16.

Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions.

Zhou D, Afzelius L, Grimm SW, Andersson TB, Zauhar RJ, Zamora I.

Drug Metab Dispos. 2006 Jun;34(6):976-83. Epub 2006 Mar 15.

PMID:
16540587
17.

Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics.

Grimm SW, Richtand NM, Winter HR, Stams KR, Reele SB.

Br J Clin Pharmacol. 2006 Jan;61(1):58-69.

18.

Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites.

Zhao XJ, Jones DR, Wang YH, Grimm SW, Hall SD.

Xenobiotica. 2002 Oct;32(10):863-78.

PMID:
12419016
19.
20.
22.

Cloning, sequencing, and functional studies of phenobarbital-inducible forms of cytochrome P450 2B and 4B expressed in rabbit kidney.

Ryan R, Grimm SW, Kedzie KM, Halpert JR, Philpot RM.

Arch Biochem Biophys. 1993 Aug 1;304(2):454-63.

PMID:
8346920
23.

Hybrid enzymes for structure-function analysis of cytochrome P-450 2B11.

Kedzie KM, Grimm SW, Chen F, Halpert JR.

Biochim Biophys Acta. 1993 Jul 10;1164(2):124-32.

PMID:
8329443
24.

Molecular basis for a functionally unique cytochrome P450IIB1 variant.

Kedzie KM, Balfour CA, Escobar GY, Grimm SW, He YA, Pepperl DJ, Regan JW, Stevens JC, Halpert JR.

J Biol Chem. 1991 Nov 25;266(33):22515-21.

Supplemental Content

Loading ...
Support Center